MedTrace Logo

Pharmacodynamic Study of TPN171H Tablets in Patients With Mild to Moderate Erectile Dysfunction

NCT05388825 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2023-02-23

No results posted yet for this study

Summary

This study is a randomized, double-blind, placebo-controlled, two-cohort, three-cycle crossover (at least a 5-day cleaning period per cycle), and a multicenter clinical trial design.

Conditions

Interventions

DRUG

TPN171H 2.5mg

TPN171H 2.5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)

DRUG

TPN171H 5mg

TPN171H 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)

DRUG

TPN171H 10mg

TPN171H 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)

DRUG

Placebo 5mg

Placebo 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)

DRUG

Placebo 10mg

Placebo 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)

Sponsors & Collaborators

  • Vigonvita Life Sciences

    lead INDUSTRY

Principal Investigators

  • Hui Jiang · Peking University Third Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-01-04
Completion
2023-02-17

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05388825 on ClinicalTrials.gov